关于靶向治疗在晚期胃癌治疗中的作用的随机试验的系统评价和荟萃分析 : 证据不翻译 ?
关键词: ADME, absorption, distribution, metabolism, and excretion Ab, monoclonal antibody BSC, best supportive care CHT, chemotherapy EGFR, epidermal growth factor receptor GC, gastric cancer HER2, human epidermal growth factor receptor 2 HER3, human epidermal growth factor receptor 3 MET, mesenchymal epithelial transition factor NGS, next generation sequencing NSCLC, non-small cell lung cancer OR, odds-ratio OS, overall survival PARP, poly ADP ribose polymerase PFS, progression free survival PI3K, phosphatidylinositide 3-kinases PRISMA, preferred reporting items for systematic reviews and meta-analyses RAF, rapidly accelerated fibrosarcoma RAS, rat sarcoma viral oncogene homolog RCTs, randomized clinical trials RR, response rate TKI, tyrosine kinase inhibitor VEGF, vascular endothelial growth factor VEGFR: VEGF receptor aGC, advanced gastric cancer angiogenesis gastric cancer mTOR, mammalian target of rapamycin mTORC, mTOR complex meta-analysis randomized clinical trials systemic chemotherapy targeted pathways targeted therapy
Mesh : Angiogenesis Inhibitors / therapeutic use Antineoplastic Combined Chemotherapy Protocols / adverse effects therapeutic use ErbB Receptors / antagonists & inhibitors Humans Molecular Targeted Therapy / methods Randomized Controlled Trials as Topic Receptor, ErbB-2 / antagonists & inhibitors Stomach Neoplasms / drug therapy epidemiology mortality Survival Analysis
来 源:
DOI:10.1080/15384047.2015.1056415
PDF(Sci-hub)
PDF(Pubmed)